cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Denali Therapeutics Inc
9 own
3 watching
Current Price
$32.67
$1.79
(5.8%)
logo-dnli
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
4,044.43M
52-Week High
52-Week High
39.43
52-Week Low
52-Week Low
20.24
Average Volume
Average Volume
1.4M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
224.4045
iconMarket Capitalization4,044.43M
icon52-Week High39.43
icon52-Week Low20.24
iconAverage Volume1.4M
iconDividend Yield--
iconP/E Ratio224.4045
What does the Denali Therapeutics Inc do?
N/A
Read More
How much money does Denali Therapeutics Inc make?
News & Events about Denali Therapeutics Inc.
Globe Newswire
8days ago
Partner Sanofi has commenced dosing in a Phase 2 clinical trial of SAR443820 (DNL788) in individuals with multiple sclerosisDenali to receive a milestone payment of $25 million from Sanofi for Phase 2 clinical trial initiationDevelopment of RIPK1 inhibitor program continues in a broad range of ...
Globe Newswire
24days ago
Four programs expected to progress in late-stage clinical studies for MPS II (Hunter syndrome), ALS, and Parkinsons diseaseFurther validation and expansion of Transport Vehicle (TV) technology, including multiple interim clinical data readouts, submission of IND for additional ETV program, and ...
Zolmax
2 months ago
Denali Therapeutics Inc. (NASDAQ:DNLI Get Rating) Director Marc Tessier-Lavigne sold 20,000 shares of the stock in a transaction that occurred on Wednesday, November 23rd. The shares were sold at an average price of $30.48, for a total value of $609,600.00. Following the transaction, the director ...
Ticker Report
2 months ago
Denali Therapeutics Inc. (NASDAQ:DNLI Get Rating) Director Marc Tessier-Lavigne sold 20,000 shares of the stock in a transaction that occurred on Wednesday, November 23rd. The shares were sold at an average price of $30.48, for a total value of $609,600.00. Following the transaction, the ...
Globe Newswire
3 months ago
SOUTH SAN FRANCISCO, Calif., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced the pricing of its underwritten public offering of 10,377,359 shares of its common stock at a price to the public of $26.50 per share. All of the shares are to be sold by Denali ...
Frequently Asked Questions
Frequently Asked Questions
What is Denali Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Denali Therapeutics Inc shares?
plus_minus_icon
How can I buy Denali Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Denali Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Denali Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Denali Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Denali Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Denali Therapeutics Inc?
plus_minus_icon
What percentage is Denali Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Denali Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$32.67
$1.79
(5.8%)
logo-dnli
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00